AAAAAA

   
Results: 1-23 |
Results: 23

Authors: Machtens, S Gansslen, A Pohlemann, T Steif, CG
Citation: S. Machtens et al., Erectile dysfunction in relation to traumatic pelvic injuries or pelvic fractures, BJU INT, 87(5), 2001, pp. 441-448

Authors: Kuczyk, MA Bokemeyer, C Hartmann, J Schubach, J Walter, C Machtens, S Knuchel, R Kollmannsberger, C Jonas, U Serth, J
Citation: Ma. Kuczyk et al., Predictive value of altered p27(Kip1) and p21(WAF/Cip1) protein expressionfor the clinical prognosis of patients with localized prostate cancer, ONCOL REP, 8(6), 2001, pp. 1401-1407

Authors: Hofner, K Oelke, M Machtens, S Grunewald, V
Citation: K. Hofner et al., Trospium chloride - an effective drug in the treatment of overactive bladder and detrusor hyperreflexia, WORLD J URO, 19(5), 2001, pp. 336-343

Authors: Becker, AJ Uckert, S Stief, CG Truss, MC Machtens, S Scheller, F Knapp, WH Hartmann, U Jonas, U
Citation: Aj. Becker et al., Possible role of bradykinin and angiotensin II in the regulation of penileerection and detumescence, UROLOGY, 57(1), 2001, pp. 193-198

Authors: Machtens, S Serth, J Bokemeyer, C Bathke, W Minssen, A Kollmannsberger, C Hartmann, J Knuchel, R Kondo, M Jonas, U Kuczyk, M
Citation: S. Machtens et al., Expression of the p53 and maspin protein in primary prostate cancer: Correlation with clinical features, INT J CANC, 95(5), 2001, pp. 337-342

Authors: Truss, MC Stief, CG Uckert, S Becker, AJ Schultheiss, D Machtens, S Jonas, U
Citation: Mc. Truss et al., Initial clinical experience with the selective phosphodiesterase-1 isoenzyme inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder, WORLD J URO, 18(6), 2000, pp. 439-443

Authors: Machtens, S Schultheiss, D Kuczyk, M Truss, MC Jonas, U
Citation: S. Machtens et al., The history of endocrine therapy of benign and malignant diseases of the prostate, WORLD J URO, 18(3), 2000, pp. 222-226

Authors: Becker, AJ Uckert, S Stief, CG Truss, MC Machtens, S Scheller, F Knapp, WH Hartmann, U Jonas, U
Citation: Aj. Becker et al., Cavernous and systemic testosterone levels in different phases of human penile erection, UROLOGY, 56(1), 2000, pp. 125-129

Authors: Becker, AJ Uckert, S Stief, CG Truss, MC Machtens, S Scheller, F Knapp, WH Hartmann, U Jonas, U
Citation: Aj. Becker et al., Possible role of human growth hormone in penile erection, J UROL, 164(6), 2000, pp. 2138-2142

Authors: Becker, AJ Uckert, S Stief, CG Truss, MC Machtens, S Scheller, F Knapp, WH Hartmann, U Jonas, U
Citation: Aj. Becker et al., Plasma levels of cavernous and systemic norepinephrine and epinephrine in men during different phases of penile erection, J UROL, 164(2), 2000, pp. 573-577

Authors: Truss, MC Becker, AJ Uckert, S Schultheiss, D Machtens, S Jonas, U Steif, CG
Citation: Mc. Truss et al., Selective pharmacological manipulation of the smooth muscle tissue of the genitourinary tract: a glimpse into the future, BJU INT, 83, 1999, pp. 36-41

Authors: Kuczyk, M Machtens, S
Citation: M. Kuczyk et S. Machtens, Predictive value of decreased p27 Kip1 protein expression for the recurrence-free and long-term survival of prostate cancer patients, PROSTATE C, 2, 1999, pp. S17-S17

Authors: Kuczyk, MA Machtens, S Bokemeyer, C Hradil, K Macheel, I Jetscho, V Hartmann, J Thon, WF Jonas, U Serth, J
Citation: Ma. Kuczyk et al., Prognostic value of p27(Kip1) and p21(WAF/Cip) protein expression in muscle invasive bladder cancer, ONCOL REP, 6(3), 1999, pp. 687-693

Authors: Serth, J Kuczyk, M Machtens, S Bokemeyer, C Herrmann, R Hartmann, J Knuchel, R Jonas, U
Citation: J. Serth et al., Analysis of the cyclin-dependent kinase inhibitor p27(Kip1) in muscle invasive bladder cancer, ONCOL REP, 6(1), 1999, pp. 229-233

Authors: Kuczyk, M Serth, J Bokemeyer, C Machtens, S Schwede, J Herrmann, R Paeslack, U Truss, MC Knuchel, R Jonas, U
Citation: M. Kuczyk et al., The need for microdissectional tumor cell preparation during the moleculargenetic analysis of prostate cancer, WORLD J URO, 17(2), 1999, pp. 115-122

Authors: Machtens, S Serth, J Kuczyk, M
Citation: S. Machtens et al., New aspects on genetic alterations and biological prognostic parameters incancer of the prostate, ONKOLOGIE, 22(4), 1999, pp. 322-325

Authors: Machtens, S Kuczyk, M Becker, AJ Bokemeyer, C Serth, J Jonas, U
Citation: S. Machtens et al., New aspects on the identification of genetic alterations and prognostically important biological parameters in renal cell cancer, UROLOGE, 38(5), 1999, pp. 442-451

Authors: Kuczyk, M Munch, T Machtens, S Wunning, T Grunewald, V Stief, CG Hofner, K Jonas, U
Citation: M. Kuczyk et al., Therapy for kidney cell carcinoma with cava thrombus. Importancy of extracorporeal circulation and prognostic value of cranial tumor extension, UROLOGE, 38(5), 1999, pp. 460-465

Authors: Beutler, S Regel, G Pape, HC Machtens, S Weinberg, AM Kremeike, I Jonas, U Tscherne, H
Citation: S. Beutler et al., Extracorporeal shock wave therapy for delayed union of long bone fractures- preliminary results of a prospective cohort study, UNFALLCHIRU, 102(11), 1999, pp. 839-847

Authors: Becker, AJ Stief, CG Truss, MC Oelke, M Machtens, S Jonas, U
Citation: Aj. Becker et al., Petroleum jelly is an ideal contact medium for pain reduction and successful treatment with extracorporeal shock wave lithotripsy, J UROL, 162(1), 1999, pp. 18-22

Authors: Kuczyk, M Machtens, S Stief, C Jonas, U
Citation: M. Kuczyk et al., Management of the post-chemotherapy residual mass in patients with advanced stage non-seminomatous germ cell tumors (NSGCT), INT J CANC, 83(6), 1999, pp. 852-855

Authors: Kuczyk, M Machtens, S Hradil, K Schubach, J Christian, W Knuchel, R Hartmann, J Bokemeyer, C Jonas, U Serth, J
Citation: M. Kuczyk et al., Predictive value of decreased p27(Kip1) protein expression for the recurrence-free and long-term survival of prostate cancer patients, BR J CANC, 81(6), 1999, pp. 1052-1058

Authors: Machtens, S Kuczyk, M Serth, J Bokemeyer, C Macheel, I Jetscho, I Hradil, K Hermann, R Hartmann, J Thon, WF Jonas, U
Citation: S. Machtens et al., Prognostic significance of cell cycle-associated genes p27(Kipf) and p21(WAF/Cip) for muscle-invasive carcinoma, AKT UROL, 29(7), 1998, pp. 341-348
Risultati: 1-23 |